From UK to Global: A Commercialization Roadmap for British Biotech Companies
Written byNeta Kela, PhDFounder & Managing Partner
From UK to Global: A Commercialization Roadmap for British Biotech Companies
The United Kingdom remains one of the most dynamic life science ecosystems in the world. With world-class universities, a strong regulatory heritage through the MHRA, access to the NHS as a sophisticated single-payer system, and a thriving venture capital landscape, UK biotech companies are well-positioned to develop transformative therapies.
But developing a therapy in the UK and commercializing it globally are two very different challenges.
For British biotech companies with ambitions beyond their home market, the path to the EU and US requires careful planning — and the strategic decisions made early in development will determine whether global expansion is smooth or painful.
The UK Advantage — and Its Limits
What Makes the UK a Strong Launch Market
The UK offers several advantages for biotech companies:
- MHRA: A respected, efficient regulatory agency with accelerated pathways including the Innovative Licensing and Access Pathway (ILAP)
- NICE: While rigorous, NICE appraisals provide a strong signal of value that resonates globally
- NHS infrastructure: A unified healthcare system that enables relatively straightforward market access once NICE approval is secured
- Talent pool: Access to world-class scientists, clinicians, and commercial leaders from the Golden Triangle (London-Oxford-Cambridge) and beyond
The Limitation
The UK pharmaceutical market represents approximately 3-4% of global pharma revenues. For most therapies, the UK alone cannot sustain a commercially viable biotech company.
Global expansion is not optional — it is essential.
The Post-Brexit Reality
Before 2021, a UK biotech company could secure EMA approval and access 27 EU member states plus the UK through a single regulatory process. Brexit fundamentally changed this.
What changed:
- Separate regulatory submissions: MHRA and EMA now require independent applications
- No mutual recognition: An MHRA approval does not grant EU market access, and vice versa
- Clinical trial complexity: Trials must comply with both UK and EU clinical trial regulations separately
- Supply chain considerations: Manufacturing, batch release, and distribution must account for UK-EU border requirements
What this means for UK biotechs:
The regulatory burden has increased. Companies must now plan and budget for parallel regulatory strategies across three major markets: UK, EU, and US. This is more complex and more expensive — but also creates an opportunity for companies that plan well to gain competitive advantage over those that don't.
Building a Global Commercialization Roadmap
Phase 1: Strategic Foundation (Preclinical to Phase 1)
Define your global target product profile
Your TPP should not be UK-centric. From the earliest stages, design it to address the evidence requirements of:
- NICE (UK)
- G-BA/IQWiG (Germany)
- HAS (France)
- FDA (US)
This means selecting comparators, endpoints, and patient populations that resonate across all target markets.
Establish your geographic prioritization
Not every market needs to launch simultaneously. Consider:
- US-first strategy: Highest pricing, largest market, but requires significant investment in regulatory and commercial infrastructure
- UK-first strategy: Familiar market, faster timeline, generates early revenue and real-world evidence — but limited market size
- Parallel UK + EU strategy: Leverages geographic proximity and shared clinical heritage
- Global simultaneous: Most ambitious, requires the most capital and organizational capability
Key decision: Where will you hold commercial rights, and where will you seek partners?
Phase 2: Development with Global Intent (Phase 1 to Phase 2)
Design clinical trials for global acceptance
A common mistake for UK biotechs is designing trials that satisfy MHRA requirements but fall short of FDA or EMA expectations. To avoid this:
- Include clinical sites in the US and EU — not just the UK
- Use comparators that are standard of care in all target markets
- Incorporate patient-reported outcomes (PROs) valued by US payers
- Generate health economics data sufficient for HTA submissions in multiple countries
Begin early payer engagement
- In the UK, engage with NICE through their Scientific Advice programme
- In Germany, seek early G-BA consultation
- In the US, conduct payer advisory boards to understand formulary requirements
- Map the evidence gaps between markets and design studies to fill them
Build regulatory relationships in parallel
- MHRA: Leverage ILAP for innovative therapies
- EMA: Use Scientific Advice and PRIME designation for eligible programmes
- FDA: Consider Pre-IND meetings and Fast Track/Breakthrough designation
Phase 3: Commercial Readiness (Phase 2 to Phase 3)
Decide on your go-to-market model for each geography
United Kingdom: Most UK biotechs can commercialize domestically with a lean team — especially for specialist therapies with a concentrated prescriber base. Key capabilities needed:
- Medical affairs and KOL engagement
- NHS market access and NICE submission expertise
- Small specialist sales force or medical science liaison (MSL) team
European Union: EU commercialization is complex due to country-by-country market access. Options include:
- Full partnership: Out-license EU rights to an established pharma company
- Selective self-commercialization: Retain rights in key markets (Germany, France) and partner for others
- Pan-EU distributor model: Use a specialist commercialization partner
United States: The US offers the highest revenue potential but requires the most investment. Options include:
- Strategic partnership: License US rights to a larger pharma company in exchange for milestones and royalties
- Build your own US presence: Establish a US subsidiary, hire commercial leadership, build market access and sales capabilities
- Hybrid: Co-commercialize with a US partner, sharing investment and returns
Key consideration: Your choice of go-to-market model should align with your fundraising strategy and investor expectations.
Phase 4: Launch Sequencing and Execution
Recommended launch sequence for UK biotechs:
Step 1: UK launch (Month 0)
- Leverage MHRA approval and NICE recommendation
- Generate early commercial traction and real-world evidence
- Build the commercial playbook that can be adapted for other markets
Step 2: Germany launch (Month 3-6)
- Germany offers free pricing in the first year post-launch (AMNOG process)
- Early German launch maximizes revenue before reference pricing takes effect
- Sets a strong price anchor for other EU markets
Step 3: US launch (Month 6-12)
- Requires FDA approval (may be on a different timeline)
- Leverage UK and EU clinical and commercial data to support US positioning
- Deploy US commercial team or activate partnership
Step 4: Rest of EU rollout (Month 12-24)
- Sequential launches in France, Italy, Spain, Nordics
- Adapt pricing and market access strategy per country
- Use real-world evidence from UK and Germany to support HTA submissions
Partnering Strategy for Global Expansion
For most UK biotech companies, going fully global alone is not realistic — nor is it necessary. Strategic partnerships can accelerate market access while preserving value.
Types of partnerships to consider:
- Licensing deals: Out-license commercial rights for specific geographies in exchange for upfront payments, milestones, and royalties
- Co-development agreements: Share development costs and risks with a partner who brings complementary capabilities
- Co-commercialization: Jointly launch and market the product, sharing investment and returns
- Distribution agreements: Use established distributors in markets where building your own presence is not justified
When to seek partners:
- Early (Phase 1-2): If you need capital and validation — but you will give up more economics
- Late (Phase 3 / pre-approval): If you have strong data and want to maximize deal terms — but the clock is ticking on launch readiness
- Post-approval: Maximum leverage on data and market validation, but potential launch delays if partner capabilities are not ready
Key principle: The best partnerships are those where each party brings something the other cannot easily replicate.
Common Pitfalls for UK Biotechs Going Global
1. Assuming MHRA approval translates globally
It doesn't. EMA and FDA have different evidence standards, and post-Brexit, there is no regulatory shortcut.
2. Underestimating US market entry costs
Building a US commercial presence requires $20-50M+ depending on therapeutic area. Budget for it early or plan for a partnership.
3. Ignoring EU launch sequencing
Launching in a low-price EU market first can permanently anchor your pricing across Europe through reference pricing.
4. Designing UK-only clinical trials
If your pivotal trial only includes UK sites with UK-relevant comparators, you may face significant hurdles with FDA and EU HTA bodies.
5. Waiting too long to build global capabilities
Commercial leadership, regulatory expertise, and market access capabilities take time to recruit and develop. Start 18-24 months before anticipated launch.
The Role of Strategic Advisory
Expanding from the UK to global markets is one of the most complex transitions a biotech company can undertake. It requires expertise spanning:
- Multi-jurisdictional regulatory strategy
- Cross-border pricing and market access
- Partnership structuring and deal negotiation
- Commercial organization design
- Investor communication and fundraising alignment
Engaging experienced advisors who have navigated these transitions before can help UK biotechs avoid costly mistakes, accelerate timelines, and maximize the value of their innovation.
Conclusion
The UK produces world-class biotech innovation. But innovation alone does not create commercial success.
British biotech companies that want to reach patients globally must think globally from day one — designing their development programmes, regulatory strategies, and commercial plans with the EU and US in mind from the earliest stages.
The companies that get this right will not just survive the post-Brexit complexity. They will turn it into a competitive advantage.
*At PXM, we help UK biotech companies build and execute global commercialization strategies across European and US markets. If you are planning your path from UK development to international launch, request an expert review.*
How PXM Helps With This
Related
Part of Capital, Licensing & M&A. Start from the pillar: For Investors & Pharma, Scout practice, Transact practice
The Delaware Flip: How European Biotechs Win US VC Funding
What a Delaware flip is, when a European biotech should do one, and what US VCs check in diligence. Includes a US-VC readiness checklist.
Biotech M&A Targets in 2026: Where Pharma Is Really Buying
Biotech M&A targets in 2026: oncology and immunology lead, CVRM fades, China licensing surges. Where buyers are spending and the red flags to check.
How to Build a Commercialization Strategy for Biotech Companies
Too many biotech companies treat commercialization as a post-approval problem. The most successful teams start building their commercial strategy years before launch — and it shapes everything from clinical trial design to fundraising.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.